Biotech News

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics (GPCR)Structure TherapeuticsEarnings

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies

Related news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

Stock data

Close
17.12 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States